These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 32354950)

  • 1. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical presentation of patients with chronic myeloid leukemia in chronic phase-Case report.
    Ramdohr F; Fabarius A; Maier B; Bretschneider D; Jauch A; Monecke A; Metzeler KH; Janssen JWG; Schlenk RF; Kayser S
    Front Oncol; 2022; 12():960914. PubMed ID: 36106102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and Clinical Implications of a Novel
    Stella S; Massimino M; Tirrò E; Vitale SR; Accurso V; Puma A; Pennisi MS; DI Gregorio S; Romano C; DI Raimondo F; Siragusa S; Manzella L
    Anticancer Res; 2019 Dec; 39(12):6965-6971. PubMed ID: 31810968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ; Jiang Q; Jiang H; Lai YY; Shi HX; Chen WM; Yu L; Huang XJ
    Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
    Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
    Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
    BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
    Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
    Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3
    Massimino M; Stella S; Tirrò E; Consoli ML; Pennisi MS; Puma A; Vitale SR; Romano C; Zammit V; Stagno F; DI Raimondo F; Manzella L
    Anticancer Res; 2019 Jul; 39(7):3949-3954. PubMed ID: 31262926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 13. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
    Berdeja JG; Heinrich MC; Dakhil SR; Goldberg SL; Wadleigh M; Kuriakose P; Cortes J; Radich J; Helton B; Rizzieri D; Paley C; Dautaj I; Mauro MJ
    Leuk Lymphoma; 2019 Oct; 60(10):2384-2393. PubMed ID: 30912699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R; Galal A
    BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
    McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
    Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
    Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
    Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A; Eskazan AE
    Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.